• Thurs news: GSK inks 2nd neuro pact in weeks. Teva episodic migraine trial. FDA clears AZ’s Imfinzi for aggressive lung cancer. Novartis fails to block generic Entresto. Nuvig gets immune drug funding. See more on our front page

How Much Longer Will This Company Be Around?























































I would be shocked if IDEV does more than $50MM a year in sales. A $240MM price tag would be completely asinine.

Again, once the docs are off the payroll, who is going to use it as a workhorse product? Not going to happen. ABT has put enough money into Absolute. They will have an SFA indication in less than 12 months. To pay $240MM for a second stent would be absolutely crazy. But stranger things have happened.

I thought COV owned approx. 25% of IDEV?
 


















So in the last week, we've heard ABT, COV, and Boston bought IDEV?

In other words, IDEV reps are trying to give the impression someone wants this POS?

IDEV selling out would be the best thing to happen to me. The invested docs get their payday, and they can start stenting with what is best for the patient again. Imagine that.